<DOC>
	<DOCNO>NCT02345590</DOCNO>
	<brief_summary>Weakening expansion main abdominal artery ( abdominal aortic aneurysm , AAA ) common problem old Australians . The majority AAAs small ( &lt; 55 mm ) affect 90,000 individual Australia 4.5 million world-wide . Currently , treatment available AAA surgery . However , surgical therapy effective small AAAs , patient undergo program repeat image consultation monitor size aneurysm symptom . This proposal aim address urgent need identify medical treatment able limit progression AAAs . The study design rationale base strong preclinical evidence support value eplerenone ( agent indicate treatment heart failure ) limit AAA progression . If proved effective , medication would : 1 . Reduce number patient require costly surgery 2 . Reduce number surgery related death complication 3 . Provide therapy suitable rapidly expand elderly age group AAAs .</brief_summary>
	<brief_title>Eplerenone Management Abdominal Aortic Aneurysms</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Individuals age 60years ( inclusive ) ; AAA measure maximum diameter 3049 mm MRI ; current indication AAA repair accord treat physician expectation revise within next year ; high likelihood compliance treatment 12 month ; stable medication regime last six month ; give sign informed consent participate study . Serum potassium concentration 5.0 mmol/L randomisation ; evidence renal impairment define serum creatinine &gt; 133 umol/L creatinine clearance &lt; 60 mL/min ; know significant renal stenosis ( &gt; 70 % ) one renal artery ; evidence liver disease ( i.e . cirrhosis hepatitis ) abnormal liver function define aspartate aminotransferase , alanine aminotransferase total bilirubin &gt; 1.5x upper limit normal ; evidence primary aldosteronism ( plasma aldosterone/renin ratio &gt; 650 pmol/L ) ; electrolyte imbalance ; active gout ; use MR antagonist ; use potassiumsparing diuretic , potassium supplement ; individual claustrophobia history metallic prosthetic implant contraindicate MRI .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>